Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BioArctic | Stoccolma | Salute | Ricerca medica e biotecnologica | 13,33 Mrd SEK | -150,8x | 1,05 | 151,40 SEK | 6,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Bioinvent | Stoccolma | Salute | Ricerca medica e biotecnologica | 3,27 Mrd SEK | -8x | 0,26 | 49,95 SEK | 4,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Devyser Diagnostics AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 2,28 Mrd SEK | -30,8x | 1,37 | 133 SEK | -3,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,9% Rialzo | Fai l’upgrade a Pro+ | |
Hansa Biopharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 2,23 Mrd SEK | -2,9x | -0,1 | 32,50 SEK | 7,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Vicore Pharma Holding AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,93 Mrd SEK | -4,6x | -0,24 | 8,19 SEK | 2,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Egetis Therapeutics AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,88 Mrd SEK | -4,8x | -0,37 | 5,18 SEK | -4,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
XSpray Pharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,48 Mrd SEK | -5,5x | 1,26 | 43,85 SEK | 1,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Cereno Scientific | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,39 Mrd SEK | -17,7x | 0,22 | 4,91 SEK | -0,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Diamyd Medical | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,33 Mrd SEK | -8x | 1,11 | 12,70 SEK | -1,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Nanoform Finland Plc | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,12 Mrd SEK | -6,7x | -7,17 | 13,16 SEK | 0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Nykode Therapeutics | Stoccolma | Salute | Ricerca medica e biotecnologica | 768,95 Mln SEK | -4,5x | 13,98 SEK | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Intellego Technologies AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 722 Mln SEK | 7,3x | 0,05 | 26,30 SEK | 1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Promimic AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 671,66 Mln SEK | -61,8x | -4,56 | 35,90 SEK | -0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Alligator Bioscience | Stoccolma | Salute | Ricerca medica e biotecnologica | 519,26 Mln SEK | -1,9x | -0,05 | 0,69 SEK | 1,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Mendus AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 488,44 Mln SEK | -3,3x | -0,06 | 9,70 SEK | 2,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Hamlet Pharma AB | Spotlight | Salute | Ricerca medica e biotecnologica | 447,93 Mln SEK | -10,6x | 0,34 | 2,67 SEK | 6,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Initiator Pharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 399,33 Mln SEK | -20,3x | -0,35 | 7,10 SEK | 2,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Curasight AS | Spotlight | Salute | Ricerca medica e biotecnologica | 375,57 Mln SEK | -7x | 0,23 | 17,93 SEK | -1,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Cantargia AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 352,68 Mln SEK | -1,5x | -0,05 | 1,92 SEK | 1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Peptonic Medical | Spotlight | Salute | Ricerca medica e biotecnologica | 345,33 Mln SEK | -0,2x | 0,005 SEK | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Alzinova | Stoccolma | Salute | Ricerca medica e biotecnologica | 344,18 Mln SEK | -9,5x | -1,46 | 3,86 SEK | 3,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
SynAct Pharma AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 325,62 Mln SEK | -2,1x | -0,11 | 7,50 SEK | -4,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Oncopeptides | Stoccolma | Salute | Ricerca medica e biotecnologica | 322,78 Mln SEK | -0,7x | -0,04 | 1,50 SEK | -2,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Saniona AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 311,04 Mln SEK | -3x | 0,05 | 2,80 SEK | 0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Medivir | Stoccolma | Salute | Ricerca medica e biotecnologica | 306,22 Mln SEK | -0,1 | 2,73 SEK | -1,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Xbrane Biopharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 305,90 Mln SEK | -0,5x | -0,01 | 0,20 SEK | 1,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Annexin Pharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 261,69 Mln SEK | -3,4x | -0,12 | 0,49 SEK | -5,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Ascelia Pharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 245 Mln SEK | -1,6x | -0,07 | 2,59 SEK | 1,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Guard Therapeutics | Stoccolma | Salute | Ricerca medica e biotecnologica | 236,06 Mln SEK | -2,5x | -0,07 | 20,40 SEK | -2,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Abliva AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 225,66 Mln SEK | -1,5x | 0,21 | 0,14 SEK | -2,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ |